Matt Cahill

Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada.

Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada.